RBC Europe’s aTyr Pharma ATYR Stock Holding History

RBC Europe’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-429	Closed	-$2.2K	–	1083
2019 Q2	$2.2K	Hold	429	–	–	﹤0.01%	981
2019 Q1	$3.3K	Hold	429	–	–	﹤0.01%	963
2018 Q4	$2.97K	Hold	429	–	–	﹤0.01%	971
2018 Q3	$4.88K	Hold	429	–	–	﹤0.01%	965
2018 Q2	$5.46K	Hold	429	–	–	﹤0.01%	954
2018 Q1	$15.9K	Hold	429	–	–	﹤0.01%	720
2017 Q4	$21K	Hold	429	–	–	﹤0.01%	667
2017 Q3	$30.3K	Buy	+429	New	+$19.9K	﹤0.01%	589

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

MCIM

Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return

RBC Europe's ATYR Position: Q3 2019 in Review

RBC Europe sold out of aTyr Pharma (ATYR) in Q3 2019, closing a stake of 429 shares — an estimated $2.2K sold.

RBC Europe first reported a position in ATYR in Q3 2017 and held it in 8 quarters. The position peaked at $30.3K in Q3 2017. 19 funds tracked by Wall St. Rank hold ATYR as of Q3 2019.

RBC Europe reported no remaining aTyr Pharma position as of Q3 2019 after selling out during the quarter.
RBC Europe sold 429 aTyr Pharma shares in Q3 2019, an estimated $2.2K.
RBC Europe first reported a position in aTyr Pharma in Q3 2017 and held it in 8 quarters.
RBC Europe's aTyr Pharma position peaked at $30.3K in Q3 2017.
19 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2019.

Based on RBC Europe's 13F filing for Q3 2019, filed 9 Nov 2023.